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Abstract Increasing the rate of biomedical research that is
relevant to clinical innovation has been an intensifying concern
of the research community and of policy-makers. In response,
some of these actors have recently promoted varied approaches
they label as translational research (TR) and translational med-
icine. Thismovement started in theUSA in the early 1990s, and
has since evolved to encompass large and ambitious initiatives.
Its advocates contend that the productivity of biomedical inno-
vation systems can be bolstered by: (1) the extension of large-
scale development collaborations; (2) the strengthening of clin-
ical experimental platforms; (3) training and supporting dedi-
cated human capital; (4) achieving higher collective
coordination of research teams than was previously common
practice. In this paper, we examine to which extent these
objectives have been put into practice by communities of
biomedical actors and policymakers, by characterizing current
translational initiatives in three European countries—Austria,
Finland and Germany. This research draws on an analysis of
policy documents and 26 semi-structured interviews conducted
with policy-makers and TR advocates from these countries.
Traditions of science and technology policy-making in each
country have made them differentially receptive to the TR
movement. German biomedical actors have most fully put into
practice TR propositions, while Finland has seen policy-level
debate of the notions but little in the way of concrete imple-
mentation and Austria appears to be a middle case.
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Pharmaceutical innovation crisis
Introduction
In the context of the Human Genome Project, high expect-
ations have been raised that the face of clinical care would be
changed drastically by the short-term arrival of improved
diagnostics and therapeutics developed by harnessing –omics
platforms. Most notably at the moment, expectations have run
high that efforts in the discovery and validation of biomarkers
could provide new tools for rational drug development, for
diagnostic interventions and for tailoring treatments based on
individuals’ molecular make-up (“personalised medicine”)
(Yap et al. 2010). Despite their potential for clinical innova-
tion, few new interventions drawing directly from these
advances have in fact reached regulatory approval, and less
still have been successfully adopted in the clinic (Pisano 2006;
Martin et al. 2009; Janssens and van Duijn 2010; Swinney and
Anthony 2011; Anonymous 2012; Hoelder et al. 2012).
Commentators have thus, in recent years, decried a situation
where the biomedical field would be sitting on a gold mine of
basic post-genomic research just waiting to be properly
exploited into clinical innovation.
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A parallel, but more recent development has also contrib-
uted to shaping perceptions that investments in biomedical
research are increasingly disconnected from improvements in
clinical practice and, especially, in therapeutic modalities.
With a landmark 2004 report of the US Food and Drug
Administration, biomedical actors worldwide started discus-
sing the possibility of an impending crisis of innovation in the
pharmaceutical industry sector (FDA 2004). Large pharma-
ceutical companies have recently had to engage in heavy
personnel cuts, because of a historical conjuncture where the
blockbuster products, usually drugs, which provided them
with most of their revenues are falling off patent without
having been gradually replaced with new such blockbusters
(MacIlwain 2011; Mittra et al. 2011). Yet, advances in post-
genomic platforms were expected to replenish the sources of
innovation in pharmaceutical research and technology devel-
opment (RTD). Taken together, these problems seem to indi-
cate the need for new means to exploit genomic knowledge,
with an aim to deliver the promises of genomic research by
improving clinical care to patients and thus justify the large
investments made in genomics projects to citizens; and pro-
vide the pharmaceutical sector with new innovation platforms
to get out of crisis.
With the goal to increase the relevance of biomedical re-
search for clinical innovation, a number of actors in biomedi-
cine and policy-making have argued for the expansion of
efforts made in the area of applied pre-clinical laboratory re-
search and early clinical research. Advocates of this view have
promoted the concept of a field of Translational Research (or
Translational Medicine or Translational Science; abbreviated to
TR here), with dedicated expertise focused on mobilizing basic
research results and clinical experience in the development of
new or improved clinical interventions. TR propositions have
been characterized by a desire to link together biological,
engineering, biochemistry and clinical competences to provide
integrated academic or public–private RTD pipelines. It is
perhaps most appropriate to talk of TR as a reform movement
within biomedical research (following Milne and Kaitin 2009),
one that aims to change both researchers’ experimental practi-
ces and policy-makers’ and academic administrators’ organisa-
tional models (Gaisser et al. 2009). There has been intense
discussion of these new propositions within the biomedical
community (Nathan 2002; Weissmann 2005; Khoury et al.
2007; Wehling 2008; Woolf 2008; Milne and Kaitin 2009;
Wehling 2010; Marincola 2011), and a number of well-
advertised and well-funded new institutions that bear the label
of TR have recently been established (Zerhouni 2005; NCI
2007; Borstein and Licinio 2011; Collins 2011;
Kupferschmidt 2011; Shahzad et al. 2011; von Roth et al.
2011). Despite all of this activity, it is still unclear to which
extent the propositions of the TR movement have effectively
led to concrete changes in both the daily experimental and
organisational practices of biomedical actors and the
orientations of those state-formulated policies that frame inno-
vation activities. This article examines the recent policies and
institutional initiatives of three European countries to answer
this question.
Understanding change in biomedical innovation:
a proposed analytical grid
Making academic research activities more relevant to industry
and civil society has been a recurring goal of science, tech-
nology and innovation policy makers since the 1980s (Guston
2000; Nowotny et al. 2001; Van der Weijden et al. 2012). In
the biomedical field more specifically, typical measures that
have been put into place by state- and institution-level policy-
makers to achieve this goal have included: the promotion of
academic entrepreneurship for the creation of specialized bio-
technology firms that can engage in RTD work (Corolleur et
al. 2004; Ebers and Powell 2007; Grimaldi et al. 2011); the
promotion of technology transfer activities, often through the
creation of dedicated offices in universities for stepping up
patent filing and facilitating contract or cooperative research
with industry (Colyvas 2007; Trippl and Tödtling 2008); the
support of mixed research networks including both academic
and private organisations (Stuart et al. 2007). Until recently,
policy-level discussions about the promotion of health inter-
vention development work in biomedicine have often re-
volved specifically around these measures (Pisano 2006;
Martin et al. 2009; Lander and Atkinson-Grosjean 2011).
The emergence of a discussion around TR model has
brought to the foreground a different set of issues in the search
to improve the productivity of biomedical innovation systems
then those discussed in the paragraph above. There has been a
multitude of claims and propositions for reform made using
the TR label. In this section, we present three core claims that
have recurrently been put forward in editorials, commentaries
but also policies about TR. Using these categories, we aim to
capture the type of scientific and institutional changes
advocated in discussions about TR. Together, they form the
basis for what we would here call the “TR model”. We will
refer to the “TR movement” to refer to this large and
unorganised group of actors that have actively advocated the
TRmodel as ameans to improve biomedical innovation systems.
Experimental platforms and research practices
Proponents of the TR model maintain that biomedical innova-
tion should make a central place to experimental practices
conducted in clinical contexts. Some representations of
biomedical innovation have had a tendency to treat clinical
research as simply a means to validate therapeutic hypotheses
that originate in laboratory experiments using animal models,
cell cultures or collections of biospecimen, for example
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(Nightingale and Martin 2004; Keating and Cambrosio 2012).
Instead TR advocates maintain that clinical research and clin-
ical care are practices productive of experimental knowledge in
their own right, that they are an important source of hypotheses
and data, and that they need to be put at the foreground of
biomedical innovation to improve productivity (Nathan 2002;
Coller 2008;Wehling 2008; CIHR 2011;Marincola 2011). The
experimental fecundity of clinical research is argued to be
especially well visible in areas such as therapeutic research into
targeted anti-cancer agents. There, new developments in “biol-
ogy-led clinical trials”, for example, transform early clinical
studies into complex experimental platforms that combine
simultaneous and interdependent clinical and laboratory areas
(Hoelder et al. 2012). Analysts of biomedical policy themselves
have indeed commented that hospitals and clinics were “hidden
innovation systems”, because these sites of knowledge produc-
tion have often been left out of the dominant representations of
innovation in the field (Lander and Atkinson-Grosjean 2011).
As such, academic medicine centres and university clinics have
been argued to form central institutions in TR initiatives
(Zerhouni 2005; FitzGerald 2009).
There is a second aspect to the arguments about the exper-
imental platforms and research practices that would be most
conducive to TR. Advocates of the approach have often con-
tended that TR projects are best conducted by large-scale
inter-disciplinary and inter-organisational collaborations. The
development of complex new health interventions (such as
small molecule drugs and biologics, advanced therapy medic-
inal products such as stem-cell treatments, diagnostics based
on gene or genome-wide sequencing technologies) necessitate
the successful combination of a variety of competences, ex-
perimental equipments and institutional routines, in addition
to close interactions between laboratory and clinic (Hörig et
al. 2005; Khoury et al. 2007; NCI 2007; Anonymous 2008;
FitzGerald 2009; Silber 2010; Collins 2011; Williams et al.
2012). Expertise in animal models, in vitro cell cultures,
typing of tissue samples, pharmaceutical chemistry in all of
its ramifications, including mass screening of compound li-
braries, medical imaging, are all mobilized in the development
of a new drug, for example. Many of these experiments have
to comply with strict regulatory standards, or necessitate cost-
ly investments in specialised equipment not commonly found
in academic institutions.While these experimental approaches
are commonly combined by the pharmaceutical industry, sim-
ilar efforts in an academic environment are mostly novel.
Training and human capital
Interdisciplinary brokers are single individuals that can legit-
imately engage in the practices of multiple scientific disci-
plines or organisations, and assist colleagues belonging to one
of these social groups to exchange with members of the other
(Calvert 2010). New professional interdisciplinary identities,
institutionalized through dedicated training programmes, can
help to stabilize emerging fields of research and the networks
that enact them. Given the high interdisciplinary and inter-
organisational character of TR, it should come as no surprise
that the emergence of this policy narrative has been accompa-
nied by claims of professional jurisdiction. Particularly,
clinician-scientists have claimed a privileged expertise in co-
ordinating and leading TR projects, resting on their dual
expertise in both experimental and clinical care practices (for
primary literature presenting those claims, see: Nathan 2002;
Coller 2008; Borstein and Licinio 2011; von Roth et al. 2011;
for social science analyses, see Wilson-Kovacs and
Hauskeller 2012). The potential authority of this interdisci-
plinary human capital is compounded by the reunion within
single TR projects of actors with a variety of backgrounds,
each bringing different frameworks for experimental practice
and for evaluating what counts as “good translational re-
search” (see Wainwright et al. 2009; Morgan et al. 2011). It
can thus be expected that other types of interdisciplinary
brokers, beside from clinician-scientists, can also be encoun-
tered in actual TR projects.
Coordination and policy
The large and complex projects of the TR enterprise necessitate
more management and coordination than what is typical for
academic research networks. Consensus and a sophisticated
division of labour are necessary to diligently work on one
single development project. This was true of biomedical inno-
vation before, but it is even more so in public TR networks,
where individual members of the consortium are likely to find
greater academic recognition by engaging in curiosity-driven
projects than by engaging in the development work required by
the consortium (Anonymous 2008). Strategic planning may be
required to make sure that the multiple actors composing
biomedical innovation systems collectively carry over new
knowledge and technologies to development phases, even
when the principal investigators responsible for these advances
are not interested in this work. To ensure a high level of
coordination in TR initiatives, commentators have devised
elaborated project planning methods (Wehling 2010; Hoelder
et al. 2012). There has also been a proliferation of models and
representations of the innovation process which assign roles
and functions to various groups of academic professionals,
essentially creating plans for sophisticated divisions of transla-
tional labour (Khoury et al. 2007; NCI 2007). Finally, there has
been mounting argumentation that a new group of professio-
nals are needed to lead TR projects, individuals that have less
capacities for creativity and curiosity than for the management
and coordination of large teams (Harrigan and Emery 2010;
Borstein and Licinio 2011). Even patient organisations or char-
ities have felt that they might have to fill such coordination
roles, with the realisation “there is no one paid to spend 100 %
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of his or her time following a problem from start to finish. This
creates a leadership gap, where foundations need to step in and
act as the focal point for the research” (Institute of Medicine
2009: 23). This argument demonstrates a broad need for coor-
dination skills, one that may be filled by a number of new or
unexpected professional groups or organisations.
It is also under this category that it is most appropri-
ate to discuss the impacts that policies formulated by
state agencies can have on the initiatives and behaviour
of biomedical actors themselves. While RTD strategies
are often put into practice by building new institutions or
establishing incentives for certain types of research (fund-
ing programmes and tax breaks), an important aspect of
policies is also to provide collective priorities and shared
means of action (Gottweis 1998; Fischer 2003). In other
words, RTD strategies provide models, blueprints or
directions for organising collaborations between different
groups. Tellingly, political scientists have talked of these
organising effects of policy-making as instances of “co-
ordinative discourse” (Schmidt 2012).
Materials and methods
An analysis of initiatives and policies dealing with TR in
Austria, Finland and Germany was completed between
September 2010 and February 2011. Data collection focused
on a document analysis of “policy formulations”, most nota-
bly governmental white papers and approximately 200 edito-
rials, commentaries and reviews about TR published in peer-
reviewed biomedical journals. The subset of policy and ini-
tiatives selected for analysis and presented in the “Results”
section were clearly labelled by their promoters as instances of
TR.
Additionally, semi-directed interviews were conducted with
policy-makers and biomedical researchers that were leading
voices in TR discussions or initiatives in their country (nine
in Austria, five in Finland and 12 in Germany—see the Annex
for the list of respondents). Interviews and documents were
coded and analysed following an analytical grid that aimed to
capture the dimensions of the historical development of the TR
discussion, organisational shaping and coordination issues in
TR projects, and the features of the experimental practices
mobilized in developing a new health intervention. As part of
our broader research programme, semi-directed interviews and
document analyses were also conducted at the level of net-
works supported by the European Commission (nine inter-
views) and other important TR institutions across Europe, as
well as in the USA (19 interviews). This set of data is not the
focus of the analysis presented in this paper, yet this material
also informs our broader understanding of how TR issues are
developing in biomedical policy.
Results
Experimental platforms and research practices
In all three countries under study here, new institutions have
been put into place with the goals to take the propositions of
the TR movement to practice. In this section, notable ini-
tiatives from each country will be detailed, acting as case
studies to track the potential changes that could be observed
at the level of local RTD practices.
Austria
Two initiatives seem to lead developments in terms of TR in
Austria. The first, the OncoTyrol consortium, brings togeth-
er more than 36 pharmaceutical and other private sector
entities with a core of three institutes from the Tyrol region:
UMIT (The Health and Life Sciences University—with its
bioinformatics and health technology assessment divisions),
the Medical University Innsbruck (with participation from
departments in experimental cell biology, pharmacology)
and Biocenter Innsbruck (including departments in molecu-
lar pathophysiology, bioinformatics). The consortium is co-
ordinated through a private limited liability company. It is
funded at the level of 24 M € for the period 2008–2012 and
13.5 M € from 2012 to 2015. Funding is provided by
governmental sources (50 %), participating universities
(5 %) and industrial partners (45 %). The consortium
involves about 85 researchers and technicians within 24
projects led by the various core institutions presented above.
Research efforts are directed towards: the pathophysiology
of cancer, notably tumour growth and anti-tumour immuni-
ty; developing tools in bioanalytics for improved biomarker
discovery and validation; the discovery and validation of
biomarkers for diagnostic purposes, for patient stratification
in clinical trials and for drug development; bioinformatics and
system biology capacities to support the other objectives and
finally, health technology assessment, public health and eco-
nomic modelling tools that are relevant for decision-making in
oncology translational efforts. The experimental systems in-
volved thus include tissue samples analysis and typing, in
vitro cell cultures, in silico modelling of drug action and
molecular binding and cohort studies for biomarker valida-
tion, but also the tools used in appraising the health politics
and economic dimensions relevant in the development of new
health interventions.
The second initiative of note is the Anna-Spiegel Centre
(ASC), a new research facility at the Medical University of
Vienna (MUV) bringing together its foremost research
groups. This centre was founded as a means to better
support existing research groups at the MUVand to provide
them with improved “Core facilities”. The goal given here is
to support efforts within the MUV that foster exchanges
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between clinical questions and related research efforts, as
well as the feedback of new findings into medical treatment.
This is accomplished by an architecture that supports inter-
action, providing easy access to a variable range of instru-
ments within the individual researcher’s bench, allowing to
easily switch between various experimental systems and
intellectual tasks. Costs for the building (41 M€) were
shared between the City of Vienna and the Austrian
Ministry for Science and Technology. This new building
provides improved infrastructures for MUV research teams,
but they are financed as before mostly through external
funding, including principal investigator grants.
In terms of experimental practices, the specific OncoTyrol
project we examined involved many exchanges between lab-
oratory and clinical contexts. The therapeutic modality being
investigated had gone through a number of exploratory
clinical studies that had contributed to shaping further
manipulations on cell cultures and in animal models.
Clinicians however were not leaders within the project.
Project leaders had also stricken collaborations with local
biotechnology firms to access good manufacturing practice-
compliant facilities, for example, extending the scope of the
project towards development practices.
Looking at the ASC case, it is striking that this initiative
did not bring substantial change to the research already done
at the MUV. The formal mission of research groups remains
to perform research that can solve problems clinicians face
daily, a continuation of the traditional agenda of experimen-
tal medicine. The scope of research projects appears to
closely follow the sum of competences possessed within
the groups centred around principal investigators. No
large-scale collaborations were institutionalized through
the creation of this separate centre, and there did not appear
to be provisions made to support the development of com-
plex health interventions such as therapeutics. It must also
be noted that a large portion of the research teams conduct
curiosity-driven projects on aspects of human molecular
pathophysiology with no immediate relevance for clinical
innovation. Although some of the research performed at the
centre is clearly driven by clinical practice, it is interesting
to notice that the physical separation of research teams from
clinical care facilities established by the creation of the ASC
runs counter to the current TR trend to combine these two
functions in single locations.
Finland
The Institute for Molecular Medicine Finland (FIMM) is the
flagship initiative for TR in Finland. It was formed as a joint
venture of the University of Helsinki, the Hospital District of
Helsinki and Uusimaa, the National Institute for Health and
Welfare, the VTT Technical Research Centre of Finland, as well
as the European Molecular Biology Laboratory. Various FIMM
researchers are involved in European initiatives funded by the
Innovative Medicines Initiative and the European Strategy
Forum on Research Infrastructures (including the European
Advanced Translational Research Infrastructure in Medicine,
Biobanking and Biomolecular Resources Research
Infrastructure and ELIXIR—involved in bioinformatics and data
management—networks) programmes. Policy-makers and other
biomedical policy actors in Finland have made their country’s
participation in these initiatives an explicit priority (Academy of
Finland 2009). FIMM also overlaps to a great extent with the
Translational Genome-Scale Biology Centre of Excellence. The
15 Centres of Excellence are considered to support the cutting-
edge of Finnish science, across all fields. TR projects at the
institute include system biology approaches to cancer pathophys-
iology and treatment, diagnostic and pharmacogenomic test
development using genomic profiling technologies, but also
research into the genomic bases of a few groups of diseases.
Based on this research portfolio, FIMM is thus firmly
positioned on the pre-clinical side of TR. Exchanges with
clinicians and the provision of patient tissue samples, for
example, are ensured through clinical cooperation groups.
Nonetheless, one does not find here the kind of complex
interdisciplinary experimental platforms integrating quasi-
industrial systems for therapeutic development that are char-
acteristic of the more ambitious proposals of the TR move-
ment. Similarly, this centre is highly focussed on laboratory-
based experiments, with no direct involvement of clinical
experts or institutions within its structure.
Looking more broadly at the Finnish biomedical innova-
tion system, the country is home to five faculties of medi-
cine, each with their associated research hospital (Kuopio,
Oulu, Helsinki, Tampere and Turku; Academy of Finland
and Swedish Research Council 2009). In the 1990s, research
campuses were built and attached to all of these university
clinics, with the intention of stepping up multidisciplinary
biomedical research activities. The local networks thus
established were called Biocentres. The recent establishment
of a competitive State subsidy funding system (EVO-fund-
ing) has also provided university clinics with additional fund-
ing for clinical research and training of physicians (Academy
of Finland 2009). However, public sector reforms in the 1990s
have decentralized competences towards municipalities (re-
gional authorities), giving these authorities an internationally
unprecedented level of competence and financial responsibil-
ity for health policy (Hakkinen and Lehto 2005). These mu-
nicipalities have in turn had a tendency to take funds
earmarked for research to finance clinical care (Academy of
Finland 2009; The Science and Technology Policy Council of
Finland 2008; Visakorpi 2009). So while the Finnish academ-
ic medical research sector seems to be facing institutional
obstacles to the conduct of TRwork, recent policy discussions
have taken up the arguments of the TR narrative in efforts to
reform local clinical research infrastructures.
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Germany
The Translational Research Alliance in Lower-Saxony
(TRAIN) offers an interesting case to illustrate the develop-
ment of TR activities in Germany. The initiative is explicitly
concerned with developing new compounds. This aim is
explicitly carried over in the shape of the collaboration and
the members it includes. TRAIN regroups seven partners that
all directly take part in various tasks and work packages of the
collaboration’s projects. These institutes are located in relative
proximity within the two largest cities of the region. Founding
members of the consortium are the Gottfried Wilhelm Leibniz
Universität Hannover, the Fraunhofer Institute for Toxicology
and Experimental Medicine (ITEM), the Hannover Medical
School (MHH), the Helmholtz Centre for Infection Research
(HZI), the Technische Universität Carolo-Wilhelmina zu
Braunschweig and the University of Veterinary Medicine
Hannover. An additional member of the consortium is the life
sciences project management firm VPM. These founding
members have launched a number of joint ventures that act
as additional members of the consortium, including:
Twincore, which brings together researchers from the
Helmholtz Centre for Infection Research with large laboratory
equipment for analyzing pharmaceutically active substances
with clinicians and laboratory scientists with a clinical back-
ground from the nearby Hannover Medical School; the Centre
for Biomolecular Drug Research, a screening and drug devel-
opment facility and the forthcoming Clinical Research Center,
linking capacities for early clinical trials to pre-clinical
laboratory facilities. Also forthcoming is a Zentrum für
Pharmaverfahrenstechnik (roughly translated as Centre for
Pharmaceutical Process Engineering), which will take the
pharmaceutical innovation and production process itself as
an object of inquiry. In addition to this web of regional
collaborations, the TRAIN consortium is a central node of
the European Strategy Forum on Research Infrastructures
(ESFRI) network European Advanced Translational
Research Infrastructure in Medicine (EATRIS) network. The
Helmholtz Centre for Infection Research is also the central
node of the National Centre for Health Research focusing on
infectious diseases. Based on the capacities that are being
regrouped here, promoters of the consortium contend that it
might well be possible to go from pre-clinical pathophysio-
logical hypothesis to lead compound to early phase II trials
entirely within the TRAIN partnership, with alliances with
pharmaceutical industry planned for later phases of clinical
testing, for regulatory approval and for commercialization.
Through its member institutions, the consortium has access
to a number of research teams working on the development of
pre-clinical therapeutic hypotheses and interventions, using
classical systems such as animal models, cell cultures and
tissue collections. However, the consortium also has access
to banks of natural compounds (HZI), mass compound
screening equipment and expertise (HZI, Centre for
Biomolecular Drug Research and Centre for Pharmaceutical
Process Engineering), pharmacology and toxicology expertise
(ITEM), skills in experimental medicine and clinical research
(MHH and ITEM), facilities for the regulatory-compliant
production and testing of new compounds (Centre for
Biomolecular Drug Research, ITEM), as well as access to
competences in strategic planning and coordination (VPM).
TRAIN thus closely resembles the prototypical consor-
tium envisioned in TR models. It brings together a number
of different but physically close centres of expertise with the
hope that their capacities can combine and complement each
other to allow advanced clinical development of new thera-
peutics within the public academic sector. Promoters of the
consortium contend that the crisis in the pharmaceutical
industry will vindicate their model, as firms in the sector
would increasingly seek to “outsource” their R-D activities
by tapping into academic development projects notably
(interview with TRAIN coordinator). TRAIN also has
strong clinical development components through the
Hannover Medical School and the Fraunhofer Institute for
Toxicology and Experimental Medicine (which both have
clinical beds reserved for clinical studies, and with the first
one having access to patients through its university clinics),
although impetus for new project development does seem
poised to originate more in individual laboratory projects
rather than from clinical care and experimentation.
Germany has a large academic medicine sector, composed
of 36 medical schools. The German medical schools captured
1.31 billion euros out of the 5.02 billion euros of third party
research funds given out to the more than 100 German univer-
sities (MFT 2011). This represented 26 % of this external
funding pool. In 2001–2002, clinicians in German university
clinics devoted 11 % of their combined total work time to
clinical or patient-oriented research (Wissenschaftsrat 2010).
Nevertheless, reforms of Hochschulmedizin (academic medi-
cine) in Germany to strengthen research capacity, and especial-
ly capacity to conduct patient-oriented biomedical research,
have been recurring points of contention for national biomed-
ical actors. Even before the policy discussion on the issue of TR
emerged at the international level, the public funding agency
for basic research (Deutsche Forschungsgemeinschaft, DFG)
and the governmental advisory body German Council of
Science and Humanities (Wissenschaftsrat) had issued a num-
ber of reports since the 1980s which decried the adversary
conditions for doing experimental medicine and clinical re-
search in the German system of medical schools and academic
hospitals (DFG 1999; Wissenschaftsrat 1986; Wissenschaftsrat
2004). The Wissenschaftsrat has often openly voiced criticism
that German university clinics were not delivering research of a
quality level that would be expected of them (Wissenschaftsrat
2010), that this research is taking place in relative isolation,
between clinical or patient-oriented research and laboratory
194 J Community Genet (2013) 4:189–201
research within university clinics needed, but also between
university clinics and other university and public institute
(members of the four national research associations) laborato-
ries. As in the case of Finland, the importance of these
criticisms for the purpose of this analysis is to show how TR
narratives have impacted or not broader efforts in institutional
reform in Germany. A first observation here would thus be that
emphasis on the vital role of clinical experimentation in
biomedical innovation is not new to the TR agenda in
Germany. Nonetheless, recent German policies have very
much adopted the language of TR advocates when they defend
the need for large-scale public networks with strong roles for
clinical research centres. This can also be seen in another
recent, major initiative by the German Federal Ministry of
Education and Research (BMBF): the establishment of six
National Centres for Health Research, consortia of university
clinics linked to a core Helmholtz Centre (the Helmholtz
Association of publicly financed research centres groups
together 18 institutes that receive major support from the
federal government, pursue long-term ‘big science’ goals that
can contribute to overcoming societal ‘grand challenges’).
Training and human capital
Austria
Little activity could be observed in Austria in terms of specific
training programmes to build human capital dedicated to TR,
although the University of Vienna is currently developing
relevant curriculum (Shahzad et al. 2011). Nonetheless, in
parallel to the establishment of the ASC, the MUV has also
worked to step up the scientific training of medical doctors,
notably by making theses containing original experimental
results a requirement of the programme. For established physi-
cians, financial support for sabbaticals taken in laboratory-
based research teams or in industry has also been increased,
offering the possibility to develop towards a clinician-scientist
career. Finally, recent funding programmes specifically target
investigations informed by clinical situations and contexts that
clinician-scientists are best positioned to lead (such as pro-
grammes for Clinical Research at the Austrian Science Fund;
Patients in Focus at the ZIT, the technology promotion agency
of the City of Vienna and the Vienna Science and Technology
Fund’s programme for the life sciences).
Finland
The Master’s Degree Programme in Translational Medicine
at the University of Helsinki is the main new training
opportunity explicitly set up for TR in the country. The
programme is aimed at biology or natural sciences students.
The curriculum should familiarize these laboratory scientists
with clinical practice and experimental medicine. The
Programme was initiated in the wake of broader reflections
in the Finnish life sciences community about how little
medical scientists were present within their own ranks,
which made acquiring medical experience by typically
laboratory-based researchers necessary. A important com-
ponent of this discussion has been a 2008 survey of the
clinical research landscape in the country conducted by the
Academy of Finland. The authors of this inquiry concluded
that career structures systematically discouraged medical
students to pursue careers with a research component, and
that clinical research more broadly was in decline in the
country (Academy of Finland and Swedish Research
Council 2009): between 2000 and 2007, the number of
MDs trained per year had risen from around 350 to about
520, while the number of PhDs awarded to holders of an
MD had fallen from 210 to about 160 (Academy of Finland
and Swedish Research Council 2009). The recent general
strategy of the Academy of Finland has also picked up this
theme, mentioning a need for increased support for
clinician-scientists and for work on proof-of-concept in
humans in therapeutic research. So while actual working
conditions for clinician-scientists seem to be problematic,
there appears to remain a desire within policy-makers and
biomedical elites to improve support for the profession.
Germany
In comparison to Austria and Finland, Germany has seen a
multiplication of educational programmes aimed specifically
at training ‘translational investigators’. These programmes
typically provide further training in competences mobilized
over the course of translational projects, such as aspects of
laboratory and clinical research, regulatory affairs and project
management. Examples are the International Research
Graduate School for Translational Biomedicine (FIRST) at
the Goethe University of Frankfurt; the Munich M4
Leading-Edge Cluster‘s Master of Science Translational
Medicine; the University of Heidelberg’s Master of Science
in Translational Medical Research; the University of Leipzig’s
Centre for Clinical Trials’Master of Science Clinical Research
and Translational Medicine and the Berlin-Brandenburg
School for Regenerative Therapies’ Clinical Scientist PhD
programme (von Roth et al. 2011)
Increased support for investigators working both in ex-
perimental medicine and in the laboratory has also been
promoted in the German health research policy. The
Roadmap for Health Research and the Health Research
Framework Programme, issued by the BMBF, both textually
used the terms of “translational research”, referred to the
research areas the notions covered as important priorities
and discussed problematic institutional situations for clinician-
scientists as important obstacles to achieving a high
performance in the area (BMBF 2007; BMBF 2010).
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Training programmes associated with TR efforts in
Germany also go beyond clinician-scientists, however. For
example, the future TRAIN Centre for Pharmaceutical
Process Engineering will include its own training programme
for “pharmaceutical engineers” as a career path distinct from
pharmacology and revolving around the study and improve-
ment of the drug innovation process itself.
Coordination and policy
Austria
Effective coordination of relevant actors had been achieved
to varying degrees within different parts of the OncoTyrol
and ASC consortia. While the OncoTyrol consortium has a
substantial financial commitment from a large number of
industrial partners, the latter do not seem to be actively
involved in development projects together with the academ-
ic partners. Rather, the industry provides funds and some
services and reagents, with the expectation that they stand a
better chance to benefit from eventual ‘breakthroughs’. The
Section on Austrian experimental platforms for TR already
reported that shared work between laboratory- and clinic-
based actors at OncoTyrol did not always put the latter
group of actors into the position of full contributors.
Coordination at that level thus appears problematic. At
another level, however, coordination was achieved through
the consortium’s strong central leadership, which ensured
that only projects with high levels of short-term clinical
relevance would obtain funding. At the ASC, in contrast,
collaborations were deemed desirable but did not appear to
be pursued to the same extent as in other cases reported on
here. There appeared to be no leader with an overview of TR
projects, and who might be in a position to attempt that most
promising leads for new health interventions would be taken
through pre-clinical and clinical development.
Recent Austrian biomedical policy has been primarily
concerned with encouraging the formation of small- and
medium-sized enterprises in the field of biotechnology. A
comparatively broad amount of funding is made available to
encourage early development and proof-of-concept research,
as well as patenting through programmes such as BRIDGE
from the Federal Ministry for Transport, Innovation and
Technology, or Technology Marketing Austria and Life
Science Austria from the Austrian Economy Service. The
Translational Research Programme of the Austrian Science
Fund (Fonds zur Förderung der wissenschaftlichen Forschung
—FWF) has similar objectives, and addresses transfer activi-
ties from all fields of science. As such, various levels of the
Austrian government have provided incentives to those aca-
demic and industry actors that elect to coordinate their inno-
vation practices.
Recent discourse about TR now highlights the desirabil-
ity of links between clinic and laboratory, especially in
discussions about a “funding gap” between basic research
(the field of the FWF) and applied research (usually funded
by the Austrian Research Funding Agency). In the wake of
these discussions, Austrian funding agencies are indeed
changing their support policies. The aforementioned
(section on Austrian experimental platforms) Clinical
Research, Patients in Focus and Vienna Science and
Technology Fund programmes do not yield large resources,
but their existence testifies to the funding agencies’
increasing belief that there are problems in the financial
support structure for TR in the country. Such initiatives
could contribute to intensified exchanges between groups
from differing organisational and disciplinary backgrounds.
Finland
Participation in the national and international networks men-
tioned in Section “Finland” have appeared to be the main
mechanism available for Finnish investigators interested in
coordinating their experimental practices with those of col-
leagues in the goal of developing a new health intervention.
The ESFRI consortia, most notably, each include a variety of
complementary expertises, and are supported by teams of
research coordinators and project managers. Finnish investi-
gators may thus scale up their results and hypotheses into
multi-national development projects through these networks.
Germany
The leaders of the TRAIN initiative opted to make dedicated
coordinators and a firm specialised in product development
central partners of their consortium. Here, questions of
leadership, project continuity and efficient coordination of
institutionally dispersed but complementary research teams
are made central elements of the consortium’s strategy.
Nevertheless, in contrast to the OncoTyrol consortium,
TRAIN does not have a central funding mechanism to
support RTD work in itself, tying its coordinative capacity
to principal investigators’ willingness to receive support for
their TR projects.
The recent federal Health Research Framework Programme
offers a potential collective agenda for biomedical innovation
that makes the speeding up of the translation of research results
into industry-developed innovative products and processes a
high priority. Privileged means to achieving this include the
intensification of exchanges between actor groups from indus-
try, laboratory-based academic contexts and clinic-based con-
texts. The concrete mechanisms expected to bring this
programme into practice also denote a concern for increasing
the strategic orientation of individual actors towards collabora-
tive development work. Aside from the six German Health
196 J Community Genet (2013) 4:189–201
Research Centres, the policy draws on initiatives to support the
achievement of methodological and ethical standards in clinical
research and the integration of teams located at university
clinics and fundamental research institutes in medical faculties
(the Integrated Research and Treatment Centres and Clinical
Study Centres support mechanisms, both launched in 2006).
Another instrument seen as a component of these coordination
efforts is the Pharmaceuticals Initiative from 2008, which pro-
vide a total of 100 million euros to three consortia that have a
clear aim to engage in work that leads to the approval and
commercialisation of new therapeutic modalities.
Discussion
Having reviewed the uptake of specific components of the
TR model, it is now possible to discuss the degree of success
that these propositions have encountered at a national level
in each of our countries. This discussion segues into an
evaluation of how institutional landscapes and policy tradi-
tions in Austria, Finland and Germany have shaped the
reception of the TR model. Table 1 summarizes the findings
presented in Section “Results” and forms the basis for this
discussion.
In Austria, TR issues have often been narrowed to ques-
tions of technology transfer and academia-industry
exchanges, with recent but modest initiatives aimed at
bringing together clinical and laboratory teams. In general,
Austrian policies have not made use of the TR model, and
have not provided encouragements for actors from a variety
of disciplinary and organisational backgrounds to come
together to work on a single project. Elsewhere, the
OncoTyrol initiative provides a clear example of the
type of large-scale public consortium proposed in TR pro-
grammes. With its industry support and clear leadership, the
consortium is poised to perform well as an “academic
pipeline”, although central integration of clinical expertise
far enough to perfectly fit. The ASC stands in direct contrast
with OncoTyrol, an initiative that is grounded in clinical
contexts and able to directly tackle questions that may arise
in daily care practices, but with no ambitions to mount
complex development projects within its walls. This later
conclusion is particularly supported by the absence of any
central authority for the Centre. Research teams located
there have retained their affiliations to their departments of
origin (surgery, cardiology, paediatrics and so forth). The
contrast between these two initiatives highlights the variety
of paths through which clinic and laboratory can collaborate
to create clinically useful innovation, whether these are
complex new therapeutics to be marketed globally or new
knowledge that allows local change in care practices.
Austrian actors, however, do not seem to have taken up
TR model components related to training and new means
of coordinating biomedical innovation (with the exception
of OncoTyrol for the latter).
Finland has historically developed outstanding compe-
tencies in genomics population research, and its science
policy agencies actively encourage knowledge and technol-
ogy transfer. Central claims of the TR movement, such as
strengthening clinical research and supporting clinician-
scientists have also been taken up in recent state policies.
The TR model goal of strengthening of clinical experimen-
tation and making it a central component of biomedical
innovation was less in evidence at FIMM. Yet, through
ESFRI networks extensive interdisciplinary and internation-
al collaborations have been established. These collabora-
tions offer institutional settings for highly coordinated TR
projects necessitating the participation of a number of
different areas of technoscientific competence. The Master
in Translational Medicine at the University of Helsinki is
another measure which is indebted to the TR model. But
there is otherwise little in the way of concrete provisions (as








OncoTyrol: yes, but limited FIMM: no; broad efforts to
improve institutional support
for research in academic
medicine centres
TRAIN: yes, but limited; broad
efforts to improve institutional
support for research in academic
medicine centres
ASC: yes, as a continuation
of previous commitments
Training and human capital No dedicated training program;
small-scale financial support for
clinician-scientists starting
to be put into place
One training programme; policy
concern to increase support for
clinician-scientists
Multiple training programmes
with various foci; broad
concerns to increase support for
clinician-scientists
Coordination and policy Multiple coordination initiatives
at the policy-level, oriented
towards academia–industry relations;
lacking coordination at project-level
TR as clear policy goal;
interdisciplinarity through EU
networks; little support for
intra-national interdisciplinarity
TR as clear policy goal;
coordination and business
management functions created at
project-level
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opposed to policy discussions) that have aimed to strengthen
national capacities in clinical experimental systems, or to
train and support groups of professionals that might act as
brokers and coordinators or TR projects.
Issues of integration and interaction between academia
and industry or between clinical and laboratory contexts
have been on Germany’s actors’ and health research policy
agenda for some time, and German biomedical actors have
taken active part in discussing the best way to improve TR
capacities and proposing models and priorities at the policy
level. German interventions for TR have been characterized
by a number of large-scale initiatives revolving around the
nation’s established centres for large-scale research, the
Helmholtz Institutes. At the same time, there has been a pro-
liferation of smaller initiatives such as specialized Master’s
degrees or university institutes that have adopted the concepts
of TR to represent their programmes. Germany thus holds
many of the components that are advocated as privileged
means to implement the TR model. The TRAIN consortium
is, in our research, the closest example we have encountered to
what one might imagine as an “academic drug pipeline”. The
consortium also involves novel practices of coordination and
professional groups of brokers. These observations do not
indicate that biomedical innovation systems in Germany are
functioning smoothly. Many respondents to our interviews
were dissatisfied with the continuing difficulties in mobilizing
a range of actors for collaborations that cross boundaries. The
establishment of the German Centres for Health Research
has sparked discussions that national university clinics were
being subordinated to centralised research administrations
(Arbeitsgemeinschaft Hochschulmedizin 2011), showing
that there can even be tensions between different compo-
nents of the TR agenda (fostering large-scale collaborations
and strengthening clinical research, in this case). Germany
definitely appears to be the country in our small sample
where the TR model has been most readily taken up. This
applies for all components of the model, which is also in
sharp contrast with what could be observed in Austria and
Finland.
Given that TR is not a unified programme, countries have
to select, adapt and modify those elements from the overall
TR concept that are most appropriate for their goals, frame
conditions and competencies. Whereas actors concerned
with the innovation deficit in pharmaceutical industry might
favour the establishment of large-scale collaborations in
their arguments about the best way to organise national
biomedical innovation systems (as the leaders of TRAIN
have), other commentators have instead privileged the role
for clinician-scientists in realising the TR agenda (as some
Finnish and German policy-makers have). It seems possible
to trace back this process of selection of certain components of
the TRmodel to previous national developments. In Germany,
the current level of attention devoted to clinician-scientists as
privileged leaders of TR projects has been prepared by the
Wissenschaftsrat’s recommendations for improving academic
medicine since 1984. This work predates the first uses of the
terms “translational research” or “translational medicine”, yet
its more recent articulations seem to have co-evolved with the
international trajectory of the TR movement. In Germany, this
co-evolution has culminated recently in the establishment of
the German Centres for Health Research. The federal govern-
ment’s rationale for the intervention takes up almost unmod-
ified the Wissenschafsrat’s contentions that university clinics
ought to be closely networked with the nation’s large number
of non-university public institutes. The initiative’s bid to fas-
ten the mobilization of new biomedical knowledge in clinical
innovation and align the innovation system towards patients
needs seem directly inspired by the TR movement. The
OncoTyrol consortium provides another interesting instance
to study the interplay between the TR model and national
idiosyncrasies in biomedical innovation. The make-up of this
consortium can be traced back to local policy-makers’
long-standing concerns with technology transfer and the
support of academia-industry joint projects. An early ver-
sion of the consortium was first assembled as a regional
Center of Excellence, created with the explicit purpose of
fostering academia-industry exchanges. Yet, in this case, the
regional cluster involved not into an incubator of start-up
biotechnology firms as national orientations may have indicat-
ed, but rather into an instance of TR large-scale development
collaboration, with strong means to exert a broad coordination
of individual research teams. Here again, propositions from the
TRmodel have inflected local practices to create new organisa-
tional forms. In summary, important propositions from the TR
model have certainly been implemented in the three countries
studied. Yet previous institutional and policy developments
have determined which components of the TR model have
been taken up and which have not. Interestingly, whereas
policy-makers in Finland and Germany appear to be key actors
in the implementation of the TR model, uptake is driven
very much by local biomedical leaders and academic
administrations in Austria.
Conclusion
Translational research has emerged as a major new approach
for the organisation of biomedical innovation systems. This
article has sought to determine the extent to which the
proposals of TR advocates have effectively been imple-
mented in policy and new initiatives in Austria, Finland
and Germany. From the results and discussion presented
above, it appears that national TR initiatives in our three
countries have developed very much in extension of histor-
ical trends and structures of biomedical RTD capacities.
Local academic administrations and policy-makers have
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drawn mostly from those components of international TR
initiatives and narratives that extend previous institutional
and experimental trajectories. Germany has seen rather in-
tensive institutional and policy activity revolving around the
proposals of TR. Finland shows mixed adoption, although
participation in EU networks offers a unique pattern of
engaging in large collaborations for the development of
complex new health interventions. Austria has seen the
establishment of a few important initiatives but compara-
tively little policy activity. The TR programme of institu-
tional and experimental reform thus remains one among
many models available to inform efforts aimed at improving
biomedical innovation systems.
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Annex: List of interview respondents
Austria
Interview 1
Two staff, FWF (Austrian Science Fund)
Interview in Vienna on September 21, 2010
Interview 2
Staff, AWS (Austrian Economy Service)
Interview in Vienna on September 23, 2010
Interview 3
Professor responsible for TR at the Medical University of
Vienna
Interview in Vienna on October 19, 2010
Interview 4
Coordinator of a Cluster at the Ludwig-Boltzmann-Society
Interview in Vienna on October 29, 2010
Interview 5
CEO of a pharmaceutical company
Interview in Vienna on December 13, 2010
Interview 6
Joint Interview with a group leader and head of a “Core
Facility” at the Anna Spiegel Center
Interview in Vienna on December 16, 2010
Interview 7
Expert on Health Technology Assessment, Ludwig-
Boltzmann-Society
Interview in Vienna on January 5, 2011
Interview 8
Group leader, Anna Spiegel Center
Interview in Vienna on December 9, 2011
Interview 9
Group leader, clinic of the Medical University of Vienna
Interview in Vienna on January 16, 2012
Finland
Interview 1
Two leaders of a training programme in Translational
Medicine, University of Helsinki
Interview 2
Director of two translational genomics initiatives,
University of Helsinki
Interview 3
Staff, Tekes, the Finnish Funding Agency for Technology
and Innovation
Interview 4
Staff, Strategic Centre for Health and Welfare, the
Federation of Finnish Technology Industries
Interview 5
Leader of research group working on the development of




Professor, University Clinic Technical University Dresden
Interview in Dresden on December 3, 2010
Interview 2
Staff, Centre for Clinical Studies, University Clinic Freiburg
Interview in Freiburg on May 25, 2011
Interview 3
Professor, University Clinic Erlangen
Interview per telephone on March 18, 2011
Interview 4
Staff, Twincore, Hannover
Interview in Hannover on October 29, 2010
Interview 5
Professor, Ludwigs-Maximillian University Clinic Munich
and Helmholtz National Research Center for Health and
Environment, Munich
Interview in Munich on March 30, 2011
Interview 6
Professor, Clinic Rechts der Isar, Technical University
Munich
Interview in Munich on February 22, 2011
Interview 7
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Staff, Association of Research-Based Pharmaceutical
Companies, Berlin
Interview in Berlin on January 5, 2011
Interview 8
Professor, University of Heidelberg, Medical Faculty
Mannheim
Interview in Mannheim on December 20, 2010
Interview 9
Professor, German National Cancer Institute, Heidelberg
Interview in Heidelberg on January 11, 2011
Interview 10
Staff, Helmholtz National Research Center for Health and
Environment, Munich
Interview in Munich on March 30, 2011
Case Study Interview 11
Staff, VPM GmbH, Hannover
Interview in Hannover on December 13, 2011
Case Study Interview 12
Professor, Eberhard Karls University Clinic Tübingen
Interview in Tübingen on December 19, 2011
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